Cellcyte Genetics Corp (SHPN) financial statements (2022 and earlier)
Company profile
| Business Address |
PMB189 BELLEVUE, WA 98006 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Prepaid expense and other current assets | ✕ | 9 | ||
| Other undisclosed current assets | 9 | |||
| Total current assets: | 9 | 9 | ||
| Noncurrent Assets | ||||
| Other undisclosed noncurrent assets | 16 | |||
| Total noncurrent assets: | 16 | |||
| TOTAL ASSETS: | 9 | 26 | ||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 208 | 119 | ||
| Accounts payable | 126 | |||
| Accrued liabilities | 82 | 119 | ||
| Debt | 3 | 2 | ||
| Due to related parties | 141 | |||
| Other undisclosed current liabilities | 214 | |||
| Total current liabilities: | 351 | 335 | ||
| Noncurrent Liabilities | ||||
| Long-term debt and lease obligation | 477 | |||
| Long-term debt, excluding current maturities | 477 | |||
| Total noncurrent liabilities: | 477 | |||
| Total liabilities: | 829 | 335 | ||
| Stockholders' equity | ||||
| Stockholders' equity attributable to parent, including: | (820) | 11,685 | ||
| Common stock, share subscribed but unissued, subscriptions receivable | (49) | (49) | ||
| Additional paid in capital | 11,734 | 11,734 | ||
| Other undisclosed stockholders' equity attributable to parent | (12,505) | |||
| Total stockholders' equity: | (820) | 11,685 | ||
| Other undisclosed liabilities and equity | (11,994) | |||
| TOTAL LIABILITIES AND EQUITY: | 9 | 26 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|
| Operating expenses | (124) | (133) | |
| Other operating expense, net | (40) | ||
| Operating loss: | (164) | (133) | |
| Interest and debt expense | 750 | ||
| Income (loss) before gain (loss) on sale of properties: | (164) | 617 | |
| Other undisclosed net loss | (31) | ||
| Net income (loss) available to common stockholders, diluted: | (164) | 586 | |
Comprehensive Income ($ in thousands)
| 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|
| Net income (loss): | (164) | 586 | |
| Comprehensive income (loss), net of tax, attributable to parent: | (164) | 586 | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.